Načítá se...
The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
First- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung cancers (NSCLCs) that harbor sensitizing EGFR mutations (i.e., exon 19 deletions or L858R). However, acquired resistan...
Uloženo v:
| Vydáno v: | Expert Rev Anticancer Ther |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4940973/ https://ncbi.nlm.nih.gov/pubmed/26943236 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/14737140.2016.1162103 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|